This Tetraphase Pharma Analyst Expects Positive Data In Mid-2015

In a report published Tuesday, analysts at Brean Capital maintained their Buy rating on

. The price target was also maintained at $50. The analysts expect the company to post positive IGNITE 2 data in mid-2015. The company shared more positive details from the Phase 3 IGNITE 1 and IGNITE 2 trials for its antibiotic eravacycline at the recent ECCMID meeting. The antibiotic has also proven to be as effective as levofloxacin so far in the IGNITE 2 trials for cUTI. In addition, "Eravacycline IV-to-oral 200mg was well tolerated with no drug-related SAEs," the analysts said. Given this positive data, the analysts expect further positive data in mid-2015, from the pivotal portion of the IGNITE 2 trials, with NDA submission for the antibiotic for both cUTI and cIAI by the year end. The company reported in December 2014 that eravacycline was successful in meeting the primary endpoint in terms of clinical response associated with cIAI in the IGNITE 1 trials. So far in the IGNITE 2 trials, the drug has been able to achieve "high cure rates against the three most common Gramnegative pathogens in the trial, Escherichia coli, Klebsiella pneumonia, and Pseudomonas, as well as against other pathogens such as Acinetobacter baumannii and ESBL-producing pathogen isolates," the analysts added.